Phase 1/2 trial of BMS-275291 in patients with human immunodeficiency virus-related Kaposi sarcoma: A multicenter trial of the AIDS malignancy consortium Academic Article uri icon

Overview

MeSH Major

  • Acquired Immunodeficiency Syndrome
  • Antineoplastic Agents
  • Imidazoles
  • Sarcoma, Kaposi

abstract

  • BMS-275291 given at a dose of 600 mg twice daily induced unacceptable toxicity. The better-tolerated schedule of 1200 mg once a day demonstrated inadequate efficacy in patients with human immunodeficiency virus-associated KS. The apoptosis assay was not helpful in predicting response.

publication date

  • March 2008

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1002/cncr.23108

PubMed ID

  • 18224669

Additional Document Info

start page

  • 1083

end page

  • 8

volume

  • 112

number

  • 5